Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Director | March 15, 2024 | March 19, 2024 |
| Profusa, Inc.PFSA · Entity 2740 | Director | January 26, 2026 | January 31, 2026 |
| Quantum Cyber N.V.QUCY · Entity 6633 | Director | July 22, 2026 | August 06, 2026 |
| Western Magnesium Corp.MLYF · Entity 126567 | Director · President, US Operations | December 13, 2021 | December 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date March 15, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2034-03-01 | Direct | 4,500,000 |
Reported balance
After 2024-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 35,000 · Balance 4,500,000 F1: Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.
Profusa, Inc.
Report date January 26, 2026 · Filed January 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,750 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Other · Acquired 107,750 · Balance 107,750 F1: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 107,750 shares of Common Stock, and (ii) 15,250 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2030-07-11 | Direct | 15,250 |
Reported balance
After 2026-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-26 · Other · Acquired 15,250 · Balance 15,250 F1: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 107,750 shares of Common Stock, and (ii) 15,250 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 107,750 shares of Common Stock, and (ii) 15,250 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members.
Quantum Cyber N.V.
Report date July 22, 2026 · Filed August 06, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-08-03 | Direct | 191,860 |
Reported balance
After 2026-07-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-07-22 · Grant · Acquired 191,860 · Balance 191,860 F1: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F2: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.
F2: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates.
Western Magnesium Corp.
Report date December 13, 2021 · Filed December 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,000 |
Reported balance
Holding disclosure · report date 2021-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 500,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2022-12-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-13 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2026-08-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-13 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 5, 2026 00:42 UTC | Quantum Cyber N.V. QUCY · Entity 6633 | GrantStock Option (Right to Buy) · Derivative | 190,840 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-085337 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,840 Underlying: Ordinary Shares · 190,840 shares Expires 2036-08-03 F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 22, 2026 Filed Aug 6, 2026 23:53 UTC Amendment | Quantum Cyber N.V. QUCY · Entity 6633 | GrantStock Option (Right to Buy) · Derivative | 191,860 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-086314 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,860 Underlying: Ordinary Shares · 191,860 shares Expires 2036-08-03 F1 · date: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F2 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. F1 · derivative.underlying_shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · balance_after: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 10:02 UTC | Quantum Cyber N.V. QUCY · Entity 6633 | GrantStock Option (Right to Buy) · Derivative | 112,859 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001213900-26-075719 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,859 Underlying: Ordinary Shares · 112,859 shares Expires 2036-07-06 Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 01:58 UTC | Profusa, Inc. PFSA · Entity 2740 | GrantStock Options · Derivative | 52,866 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-26-009029 · ownership.xml · derivative · entry 2 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,866 Underlying: Common Stock · 52,866 shares Expires 2036-01-26 F2 · shares: Represents an annual director award of options to purchase common stock. The options vest on the first anniversary of the Closing. Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 01:58 UTC | Profusa, Inc. PFSA · Entity 2740 | GrantStock Options · Derivative | 221,794 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-26-009029 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,794 Underlying: Common Stock · 221,794 shares Expires 2036-01-26 F1 · shares: Represents an inaugural director award of options to purchase common stock. The options vest in three equal annual increments over a period of three years from the closing of the business combination between the Issuer (formerly known as NorthView Acquisition Corp.) and Profusa, Inc. (the "Closing"). Read SEC document |
| January 26, 2026 Filed Jan 31, 2026 02:50 UTC | Profusa, Inc. PFSA · Entity 2740 | OtherWarrants · Derivative | 15,250 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001213900-26-010492 · ownership.xml · derivative · entry 2 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2030-07-11 F1 · kind: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 107,750 shares of Common Stock, and (ii) 15,250 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. Read SEC document |
| January 26, 2026 Filed Jan 31, 2026 02:50 UTC | Profusa, Inc. PFSA · Entity 2740 | OtherCommon Stock | 107,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-010492 · ownership.xml · nonDerivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,750 F1 · kind: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 107,750 shares of Common Stock, and (ii) 15,250 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. F1 · price: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 107,750 shares of Common Stock, and (ii) 15,250 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:24 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 35,000 | $35,000.00 Strike: $0.01 | $1,225,000,000.00 |
DisclosureSEC source: 0001096906-24-000515 · form4.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500,000 Underlying: Common Stock · 3,500,000 shares Expires 2034-03-01 F1 · shares: Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.